De Solidarite Des Travai Fonds Sells 47,854 Shares of enGene Holdings Inc. (NASDAQ:ENGN) Stock

enGene Holdings Inc. (NASDAQ:ENGN) major shareholder De Solidarite Des Travai Fonds sold 47,854 shares of enGene stock in a transaction on Monday, April 22nd. The stock was sold at an average price of $15.00, for a total transaction of $717,810.00. Following the completion of the transaction, the insider now directly owns 3,036,153 shares in the company, valued at $45,542,295. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Large shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

De Solidarite Des Travai Fonds also recently made the following trade(s):

• On Thursday, April 18th, De Solidarite Des Travai Fonds sold 4,575 shares of enGene stock. The stock was sold at an average price of $15.01, for a total transaction of $68,670.75.

enGene Price Performance

Shares of NASDAQ:ENGN opened at $14.80 on Tuesday. The stock has a 50 day moving average price of $16.11. enGene Holdings Inc. has a 52-week low of $6.69 and a 52-week high of $43.00.

Hedge Funds Weigh In On enGene

Institutional investors have recently added to or reduced their stakes in the company. Vivo Capital LLC bought a new stake in shares of enGene during the 4th quarter valued at $6,264,000. BVF Inc. IL bought a new stake in enGene during the fourth quarter worth about $20,777,000. Omega Fund Management LLC purchased a new stake in enGene in the fourth quarter worth about $10,441,000. Finally, Fcpm Iii Services B.V. purchased a new stake in enGene in the fourth quarter worth about $80,097,000. Institutional investors own 64.16% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have recently commented on ENGN. Morgan Stanley started coverage on shares of enGene in a research note on Friday, March 8th. They set an “overweight” rating and a $40.00 price objective for the company. Wells Fargo & Company started coverage on enGene in a report on Monday. They issued an “overweight” rating and a $30.00 price objective for the company. Guggenheim started coverage on enGene in a research note on Monday, April 15th. They set a “buy” rating and a $34.00 target price on the stock. Leerink Partnrs restated an “outperform” rating on shares of enGene in a report on Tuesday, February 20th. Finally, UBS Group began coverage on shares of enGene in a report on Thursday, March 28th. They issued a “buy” rating and a $37.00 price target on the stock. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $34.40.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.